Stay updated with breaking news from Mark Vaeck. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Alphabodies cross over the boundaries between biologics and small chemical drugs Complix NV, a biopharmaceutical company focused on the discovery and development of Alphabodies, a class of protein therapeutics that are active against both extracellular and intracellular disease targets, announces that it will provide an update on new developments w
Half a century ago, the first genetically modified organism ushered in a new era of biological innovation. To mark this anniversary, here are eight milestone GMOs. Many have had, or are poised to have, a dramatic impact on our lives.
MyNEO Therapeutics to focus on building proprietary product pipeline based on a novel class of shared therapeutic cancer targets derived from the dark genome named “camyotopes” Lead product CAMYO-01 incorporates a pool of colorectal cancer-specific camyotopes formulated into an mRNA-based vaccineCAMYO-01 is advancing towards clinical development for the treatment of colorectal cancer GHENT, Belgium – October 25th 2023. myNEO, a biotech company focused on exploiting “dark genome” targets to devel
myNEO Therapeutics to focus on building proprietary product pipeline based on a novel class of shared therapeutic cancer targets derived from the dark...
Since the first genetically modified organism 50 years ago, GMOs have brought us disease-resistant crops, new drugs and more.